SCHEDULE 14A
(Rule 14a-101)

INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION

PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES
EXCHANGE ACT OF 1934 (AMENDMENT NO. __)

Filed by the Registrant |X|
Filed by a party other than the Registrant |_|

Check the appropriate box:

|_| Preliminary Proxy Statement |_| Confidential, for Use of the
|X| Definitive Proxy Statement Commission Only (as permitted by
|_| Definitive Additional Materials Rule 14a-6(e)(2))
|_| Soliciting Material Pursuant to
Rule 14a-11(c) or Rule 14a-12

Human Pheromone Sciences, Inc.
----------------------------------------------------------
(Name of Registrant as Specified in Its Charter)

------------------------------------------------------------------------
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of filing fee (Check the appropriate box):

|X| No fee required.

|_| Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.

(1) Title of each class of securities to which transactions applies:

(2) Aggregate number of securities to which transactions applies:

(3) Per unit price or other underlying value of transaction computed pursuant
to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is
calculated and state how it was determined):

(4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:

|_| Fee paid previously with preliminary materials.

|_| Check box if any part of the fee is offset as provided by Exchange
Act Rule 0-11(a)(2) and identify the filing for which the offsetting
fee was paid previously. Identify the previous filing by
registration statement number, or the Form or Schedule and the date
of its filing.

(1) Amount previously paid:

(2) Form, Schedule or Registration Statement No.:

(3) Filing party:

(4) Date filed:

HUMAN PHEROMONE SCIENCES, INC.

Notice of Annual Meeting of Shareholders
to be held June 18, 2003
------------------------------------

To the Shareholders of Human Pheromone Sciences, Inc.:

The annual meeting of shareholders (the "Annual Meeting") of Human
Pheromone Sciences, Inc. (the "Company" or "HPS") will be held at the offices of
Heller Ehrman White & Mc Auliffe LLP, 275 Middlefield Road, Menlo Park,
California, on June 18, 2003, at 10:00 am local time, for the following
purposes:

(1) To elect five Directors to hold office until the next Annual
Meeting;

(2) To act upon such other business as may properly come before the
meeting.

These items of business are more fully described in the Proxy Statement
accompanying this notice.

Only shareholders of record at the close of business on April 21, 2003,
are entitled to notice of, and to vote at the Annual Meeting and any
adjournments or postponements thereof.

All shareholders are cordially invited to attend the meeting in person.
However, to assure your representation at the meeting, please mark, sign, date
and return the enclosed proxy card as soon as possible in the postage-prepaid
envelope enclosed for that purpose. Any shareholder attending the meeting may
vote in person even if the shareholder has returned a proxy.

BY ORDER OF THE BOARD OF DIRECTORS

Julian N. Stern, Secretary

San Jose, California
April 28, 2003

================================================================================
WHETHER OR NOT YOU EXPECT TO ATTEND THE ANNUAL MEETING IN PERSON, PLEASE SIGN
AND RETURN THE ENCLOSED PROXY AS SOON AS POSSIBLE IN THE ENCLOSED POSTPAID
ENVELOPE. THANK YOU FOR ACTING PROMPTLY.
================================================================================

HUMAN PHEROMONE SCIENCES, INC.
84 West Santa Clara Street, Suite 720
San Jose, California 95113
Telephone: (408) 938-3030

-----------------------------
PROXY STATEMENT
-----------------------------

INFORMATION CONCERNING SOLICITATION AND VOTING

The enclosed proxy is solicited on behalf of the Board of Directors
(the "Board") of Human Pheromone Sciences, Inc., a California corporation (the
"Company"). The proxy is solicited for use at the annual meeting of shareholders
(the "Annual Meeting") to be held at 10:00 a.m. local time on June 18, 2003, at
the offices of Heller Ehrman White & McAuliffe LLP, 275 Middlefield Road, Menlo
Park, California. The approximate date on which this proxy statement and
accompanying notice and proxy are being mailed to shareholders is May 5, 2003.

Record Date and Shares Outstanding

Only shareholders of record at the close of business on April 21, 2003,
are entitled to notice of, and to vote at the Annual Meeting and any
adjournments or postponements thereof. At the close of business on that date,
the Company had outstanding 3,429,839 shares of Common Stock, 1,433,333 shares
of Series AA Preferred Stock (which are entitled to 642,611 votes) and 17,448
shares of Series BB Preferred Stock (which are entitled to 1,191,636 votes).
Holders of a majority of the outstanding shares of common and the outstanding
shares of preferred stock of the Company, either present in person or by proxy,
will constitute a quorum for the transaction of business at the Annual Meeting.

Revocability of Proxies

Any shareholder giving a proxy in the form accompanying this proxy
statement has the power to revoke the proxy prior to its exercise. A proxy can
be revoked by an instrument of revocation delivered prior to the Annual Meeting
to the Secretary of the Company, by a duly executed proxy bearing a later date
or time than the date or time of the proxy being revoked, or at the Annual
Meeting if the shareholder is present and elects to vote in person. Mere
attendance at the Annual Meeting will not serve to revoke a proxy.

Voting and Solicitation

On all matters that come before the Annual Meeting, holders of the
Series AA Preferred Stock are entitled to 0.448 of a vote for each share of
Series AA Preferred Stock held and holders of the Series BB Preferred Stock are
entitled to 68 votes for each share of Series BB Preferred Stock held; all
common shareholders are entitled to one vote for each share held. In the
election of Directors, the holders of Series AA Preferred Stock are entitled to
elect one director, and the holders of Series BB Preferred Stock and Common
Stock voting together as a single class elect the remaining four directors. Mr.
Kaufman has been nominated for election by the holders of the Series AA
Preferred Stock, and the other four nominees have been nominated for election by
holders of Common Stock and Series BB Preferred Stock.

A shareholder has the right to request cumulative voting for the
election of directors by giving notice of such shareholder's intention to
cumulate votes at the meeting prior to the voting. Cumulative voting allows a
shareholder to cast that number of votes which equals the number of directors to
be elected by such shareholder multiplied by the number of votes the Shares held
by such shareholder are entitled to and to distribute those votes among the
nominees as the shareholder may choose. However, no shareholder shall be
entitled to vote for more than one candidate to be elected by the Series AA
Preferred Stock or more than four candidates to be elected by holders of Common
Stock and Series BB Preferred Stock, and votes may not be cast in favor of a
candidate unless the candidate's name has been placed in nomination prior to the
voting. In the election of Directors, the candidate

-2-

receiving the highest number of affirmative votes of the Series AA Preferred
Stock and the four other candidates receiving the highest number of affirmative
votes of the Series BB Preferred Stock and the Common Stock represented and
voting at the Annual Meeting will be elected directors.

Abstentions and broker non-votes will be counted in determining whether
a quorum is present at the Annual Meeting. Generally, abstentions are counted as
votes against a proposal for purpose of determining whether or not a proposal
has been approved, whereas broker non-votes are not counted for such purpose.

The Company will bear the entire cost of solicitation, including
preparation, assembling and mailing this proxy statement, the proxies and any
additional material which may be furnished to shareholders. The Company will,
upon request, reimburse the reasonable charges and expenses of brokerage houses
or other nominees or fiduciaries for forwarding proxy materials to, and
obtaining authority to execute proxies from, beneficial owners for whose
accounts they hold shares of Common Stock. The original solicitation of proxies
by mail may be supplemented by telephone, telegram and/or personal solicitation
by directors, officers or employees of the Company. No additional compensation
will be paid for such services.

-3-

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth certain information regarding the
beneficial ownership of the Company's Common Stock (including shares of Series
AA and Series BB Preferred Stock, on an as-converted to Common Stock basis) as
of March 31, 2003 by: (i) each person who is known by the Company to own
beneficially more than 5% of the outstanding shares of Common Stock; (ii) each
of the Company's executive officers named in the Summary Compensation Table;
(iii) each of the Company's directors; and (iv) by all directors and executive
officers as a group. In computing the number of shares beneficially owned by a
person and the percentage of ownership of that person, shares of Common Stock
subject to options held by that person that are currently exercisable or
exercisable within 60 days of March 31, 2003 (see notes (1) and (6) for
exceptions) are deemed outstanding. Such shares, however, are not deemed
outstanding for the purpose of computing the percentage ownership of each other
person. The percentage of beneficial ownership is based on 3,429,839 shares of
Common Stock outstanding as of March 31, 2003. Except as otherwise indicated,
the Company believes that the beneficial owners of the securities listed below,
based on information furnished by such owners, have sole investment and voting
power with respect to the Common Stock shown as being beneficially owned by
them:

Directors, Nominees, Officers And 5% Stockholders Shares Beneficially Owned Percent Of Class
------------------------------------------------- ------------------------- ----------------

William P. Horgan (1) 125,733 3.6 %

Bernard I. Grosser, M.D.(2) 138,572 4.0

Helen C. Leong(3) 109,708 3.1

Michael D. Kaufman(4) 2,181,468 41.3

Robert Marx(5) 97,741 2.8

All executive officers and directors as a group 2,653,222 47.8
(5 persons) (6)

- --------------------

(1) Includes 118,000 shares issuable on exercise of outstanding options, of
which 98,333 are exercisable of March 31, 2003.

(2) Includes 57,499 shares issuable on exercise of outstanding options.

(3) Includes 57,499 shares issuable on exercise of outstanding options.

(4) Includes 279,166 shares of Common Stock held in the name of
partnerships and 44,167 shares of Common Stock issuable on exercise of
outstanding options. Also includes 635,474 shares issuable on
conversion of Series AA Preferred Stock and 1,173,251 shares issuable
on conversion of Series BB Preferred Stock held in the name of
partnerships, which shares represent 100% of the outstanding shares of
each of the Series AA Preferred and Series BB Preferred Stock.

(5) Includes 54,166 shares issuable on exercise of outstanding options.

(6) Includes the shares identified in footnotes (1) through (5) above.

-4-

PROPOSAL 1 -- ELECTION OF DIRECTORS

Each of the five directors to be elected will hold office until the
next annual meeting of the shareholders or until a successor shall be elected
and qualified. The following individuals are proposed for election:

Name Age Principal Occupation
- ---- --- --------------------

William P. Horgan* 55 Chairman of the Board of Directors, Chief
Executive Officer and Director

Bernard I. Grosser, MD* 74 Director

Michael D. Kaufman** 62 Director

Helen C. Leong* 75 Director

Robert Marx* 72 Director

- --------------------

* Nominee to be voted on by the holders of Common Stock and Series BB
Preferred.

** Nominee to be voted on by the holders of Series AA Preferred Stock.

William P. Horgan was appointed Chairman of the Board in November 1996
after serving as President, Chief Executive Officer and Director since January
1994, when he joined the Company. From May 1992 to January 1994, he served as
Chief Financial and Administrative Officer of Geobiotics, Inc., a
biotechnology-based development stage company.

Bernard I. Grosser, MD has served as a Director since March 1992. Dr.
Grosser is Chairman of the Department of Psychiatry at the University of Utah
and has served in that capacity since 1982. Dr. Grosser has conducted extensive
research related to hormonal target areas of the brain.

Michael D. Kaufman, a Director since August 1997, is Managing General
Partner of MK Global Ventures, a firm he founded in 1987. Prior to 1987, Mr.
Kaufman spent six years as a General Partner of Oak Investment Partners, where
he was involved in the formation of numerous technology companies. He has served
as founding investor and director of Businessland, Concerto Software, Katun,
Easel, Ekco, Interlan and Zycad, among others. Prior to becoming a Partner of
Oak Investment Partners, Mr. Kaufman was President and COO of Centronics Data
Corporation, a $150 million NYSE-listed manufacturer of computer-related
printing devices. Mr. Kaufman currently serves on the Board of Directors of
Concerto Software, Asante Technologies, and Disc, Inc., whose shares of stock
are registered under the Exchange Act. He also serves as a director of several
other privately-held companies.

Helen C. Leong has served as a Director since April 1993. Mrs. Leong is
and has been for more than five years the managing partner of Leong Ventures,
which makes investments in the areas of biogenetics and health-oriented
technologies. She is a general partner of CLW Associates, which specializes in
real estate and start-up businesses in consumer fields. Mrs. Leong is also a
founder of Mid-Peninsula Bank of Palo Alto where she has served as a director
since 1988.

Robert Marx has served as a Director since October 1994. Mr. Marx was
the founder and Co-Chief Executive Officer of Gildamarx Incorporated, a firm
specializing in designing and manufacturing exercise apparel and products for
active lifestyles from 1979 until the sale of the company in 1996. He is a
former member of the Executive Committee of the Sports Apparel Products Council
and the Board of Directors of the California Manufacturers Association, and a
member of the Executive Committee of the Board of Governors of the City of Hope.

There are no family relationships among directors or executive officers
of the Company.

-5-

Required Vote

The nominee receiving the highest number of affirmative votes of the
Series AA Preferred Stock and the four other nominees receiving the highest
number of affirmative votes of the Common Stock and Series BB Preferred Stock
present or represented and entitled to be voted for them will be elected as
directors.

THE BOARD OF DIRECTORS RECOMMENDS THAT THE SHAREHOLDERS VOTE "FOR" THE ELECTION
OF THE NOMINEES.

-6-

Board Compensation

Directors currently are not compensated for attending Board meetings,
but are reimbursed for their reasonable expenses incurred in attendance. The
Company's Non-Employee Directors' Stock Option Plan (the "Directors' Plan")
provides for the automatic grant of 8,333 shares of Common Stock if a person who
is neither an officer nor an employee of the Company and who has not previously
been a member of the Board is elected or appointed director. Each such option
will become exercisable at the rate of one-twelfth of the number of shares
covered by the option each month following the grant date, so long as the
individual is serving as a director, with full vesting over one year. In
addition, in June of each year, the Company is required to grant to each
non-employee director a 10-year Non-Qualified Option to purchase 3,333 shares of
the Company's Common Stock at an exercise price equal to the fair market value
of Common Stock on the date of the grant. These options will vest one-twelfth
per month after the date of grant, as long as the individual is serving as a
director, with full vesting over one year. The exercise price of all options
granted pursuant to the Directors' Plan is the fair market value of the
Company's Common Stock at the time of grant. A total of 137,000 shares are
reserved for issuance under the Directors' Plan.

Board Meetings and Committees of the Board

The Board of Directors met six times in 2002. Each director
participated in at least 75% of the meetings of the Board.

The Board of Directors has an Audit Committee and a Compensation and
Stock Option Committee.

The Audit Committee of the Board of Directors, whose members are Mr.
Kaufman, Dr. Grosser, and Mrs. Leong, held one meeting during 2002, with all
director members in attendance at such meeting. The Audit Committee's purpose is
to consult with the Company's independent auditors concerning their audit plans,
the results of the audit, the Company's accounting principles and the adequacy
of the Company's general accounting controls.

REPORT OF THE AUDIT COMMITTEE

The Audit Committee of the Board of Directors of Human Pheromone
Sciences, Inc. serves as the representative of the Board for general oversight
of the Company's financial accounting and reporting process, system of internal
controls, audit process, and process for monitoring compliance with laws and
regulations. Each of the members of the Audit Committee is independent, as
defined under the listing standards of NASDAQ. The committee operates under a
written charter adopted by the Board. HPS management has primary responsibility
for preparing the Company's financial statements and for the Company's financial
reporting process. The Company's independent auditors, Singer Lewak Greenbaum &
Goldstein, LLP, are responsible for expressing an opinion on the conformity of
the Company's audited consolidated financial statements to accounting principles
generally accepted in the U.S.

In this context and in connection with the audited consolidated
financial statements contained in the Company's Annual Report on Form 10-KSB,
the Audit Committee:

o reviewed and discussed the audited consolidated financial statements
with the Company's management, including a discussion of the quality of
the accounting principles;

o discussed with Singer Lewak Greenbaum & Goldstein, LLP, the Company's
independent auditors, their judgment as to the quality of the Company's
accounting principles, as well as certain matters related to the
conduct of the audit, as required by Statement of Auditing Standards
No. 61, "Communications with Audit Committees";

o met with the independent auditors, with and without management present,
to discuss the results of their examination, their evaluations of the
Company's internal controls, and the overall quality of the Company's
financial reporting;

-7-

o reviewed the written disclosures required by Independence Standard
Board Standard No.1, "Independence Discussions with Audit Committees,"
discussed with the auditors their independence from the Company, and
concluded that the non-audit services performed by Singer Lewak
Greenbaum & Goldstein, LLP are compatible with maintaining their
independence; and

o instructed the independent auditors that the Committee expects to be
advised if there are any subjects that require special attention.

Based upon the Audit Committee's discussions with management and the
independent accountants, and upon the Audit Committee's review of the
representations of management and the independent accountants, the Audit
Committee recommended to the Board of Directors that the audited financial
statements for the fiscal year ended December 31, 2002 be included in the
Company's Annual Report on Form 10-KSB, for filing with the Securities and
Exchange Commission.

Audit Committee:

Michael D. Kaufman,
Bernard I. Grosser,
Helen Leong

Relationship with Independent Accountants

Singer Lewak Greenbaum & Goldstein, LLP was retained as the Company's
independent auditors for the years ended December 31, 2002 and 2001. In
accordance with standard policy both Singer Lewak Greenbaum & Goldstein, LLP
periodically change the individuals who are responsible for the Company's audit.

In addition to performing the audit of the Company's consolidated
financial statements for the year 2002, Singer Lewak Greenbaum & Goldstein, LLP
provided various other services during the year. The aggregate fees billed for
2002 are as follows:

Audit Fees (2002 audit) $ 63,526

All Other Fees $ 7,433

All other fees consist of tax consultations and preparation of Federal
and State Tax Returns. Singer Lewak Greenbaum & Goldstein, LLP did not provided
any services related to financial information systems design and implementation
during 2002.

The Company does not anticipate that representatives from Singer Lewak
Greenbaum & Goldstein, LLP will be present at the annual meeting.

Compensation Committee

The Compensation and Stock Option Committee of the Board of Directors,
whose members are Mr. Kaufman, Dr. Grosser and Mr. Marx, held one meeting during
2002, with all director members in attendance at the meeting. The Compensation
Committee is responsible for determining salaries, incentives and other forms of
compensation for officers and other employees of the Company and administers
various and benefit plans.

-8-

EXECUTIVE COMPENSATION

The following table sets forth the total compensation for 2002, 2001
and 2000 of the Chief Executive Officer and each of the other executive officers
of the Company whose total salary and bonus for 2002 exceeded $100,000 (the
"Named Officers").

SUMMARY COMPENSATION TABLE

Long-Term
Annual Compensation Compensation
------------------- Award
-----
Securities
Underlying Other
Name and Principal Position Year Salary Options (#) Compensation(A)
--------------------------- ---- ------ ----------- ---------------

William P. Horgan 2002 $208,000 -- $ 18,000
Chairman of the Board and Chief 2001 $201,096 -- $ 18,000
Executive Officer 2000 $193,000 118,000 $ 18,000

- --------------------

(A) Mr. Horgan was granted an automobile allowance of $18,000 per year, payable
semimonthly, in October 1999.

Stock Options Granted in the Fiscal Year Ended December 31, 2002

The following table sets forth information with respect to stock
options granted during the fiscal year ended December 31, 2002 to each of the
named executive officers. All options were granted under EROX Corporation Stock
Option Plan. Options granted under the Plan become exercisable over periods not
to exceed four years and expire not more than 10 years from date of grant.

% of Total
Number of Options
Securities Granted to
Underlying Employees Exercise
Options in Fiscal Price Per Expiration
Name Granted Year Share Date
---- ------- ---- ----- ----

William P. Horgan 0 0% --

Aggregated Option Exercises in Last Fiscal Year and Fiscal Year End Option
Values

The following table sets forth certain information concerning the
number of unexercised options held as of December 31, 2002 by the Named
Officers.

-9-

Number of Securities
Underlying Unexercised Value of Unexercised
Options at In-the-Money Options at
December 31, 2002 December 31, 2002
Name Exercisable/Unexercisable Exercisable/Unexercisable
---- ------------------------- -------------------------
(#) ($)(1)
--- ------

William P. Horgan 88,500/29,500 $ 0 / $ 0

- --------------------

(1) Assuming a stock price of $.07 per share, which was the closing price
of a Share of Common Stock reported on the NASDAQ National Market on
December 31, 2002.

EQUITY COMPENSATION PLAN INFORMATION

Number of securitites
Number of securities remaining available for
to be issued upon Weighted-average future issuance under equity
exercise of exercise price of compensation plans(excluding
outstanding options, outstanding options, securities reflected in
Equity Compensation Plans warrants and rights warrants and rights column(a))
------------------------- ------------------- ------------------- ----------

Equity compensation plans approved by
security holders 482, 000 $ 3.82 386,170

Equity compensation plans not
approved by security holders -- -- --

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

In 1991, the Company transferred to Pherin Corporation ("Pherin"), a
newly formed California corporation, all of the Company's rights to its human
pheromone technology for use other than in the consumer products field, together
with $2 million in cash, in exchange for all of the stock of Pherin. Upon
approval by its shareholders at the Annual Meeting, held in August 1991, the
Company distributed to its shareholders all of the stock of Pherin. Certain
stockholders identified under "Principal Stockholders" above are also
stockholders of Pherin.

HPS and Pherin had been parties to a research and development agreement
and a supply agreement since 1996. Both agreements were terminated in 2002. The
R & D agreement was terminated on October 31, 2002 and the Company is now
directly managing all research and development efforts. In December 2002 the
company established direct relationship with qualified a vendor for its
synthesized human pheromones inventory requirements.

-10-

SECTION 16(a) BENEFICIAL OWNERSHIP

Section 16(a) of the Securities Exchange Act of 1934, as amended,
requires the Company's directors and executive officers, and persons who own
more than 10% of the outstanding shares of the Company's Common Stock, to file
with the Securities and Exchange Commission initial reports of ownership (Form
3) and changes in ownership of such stock (Forms 4 and 5).

To the Company's knowledge, based solely upon review of the copies of
such reports and certain representations furnished to it, all Section 16(a)
filing requirements applicable to its executive officers and directors were
complied with during the year ended December 31, 2002.

WHERE YOU CAN FIND MORE INFORMATION

We are subject to the reporting requirements of the Securities Exchange
Act of 1934 and file reports, proxy statements and other information with the
Securities and Exchange Commission. You may read and copy any material we file
with the Securities and Exchange Commission at its public reference rooms in
Washington, D.C., New York, New York and Chicago, Illinois. Please call the
Securities and Exchange Commission at 1-800-SEC-0330 for further information on
the public reference rooms. Our public filings are also available to the public
from commercial document retrieval services and at the web site maintained by
the SEC at http://www.sec.gov.

The SEC allows us to "incorporate by reference" into this document.
This means that we can disclose important information to you by referring you to
another document filed separately with the SEC. The information incorporated by
reference is deemed to be part of this document, except for any information
superseded by information in this document. This document incorporates by
reference the documents set forth below that we have previously filed with the
SEC. These documents contain important information about our finances and us.

1. Human Pheromone Sciences, Inc.'s Annual Report on Form 10-KSB for
the fiscal year ended December 31, 2002; and

2. Human Pheromone Sciences, Inc.'s Quarterly Reports on Form 10-QSB
for the fiscal quarters ending March 31, June 30 and September 30 of
each year.

We are also incorporating by reference additional documents that we may
file with the SEC between the date of this document and the date of the Special
Meeting.

You can obtain copies of our Annual Report as well as any of the other
incorporated documents by contacting us. We will send you the documents
incorporated by reference without charge.

Shareholders may obtain documents incorporated by reference in this
document by requesting them in writing or by telephone from the following:
William P. Horgan, Human Pheromone Sciences, Inc., 84 West Santa Clara Street,
Suite 720, San Jose, California 95113, Telephone: (408) 938-3030.

If you would like to request documents from us, including any documents
we may subsequently file with the SEC before the meeting, please do so by June
6, 2003 so that you will receive them before the meeting.

OTHER BUSINESS

The Board of Directors knows of no business that will be presented for
consideration at the Annual Meeting other than as stated in the Notice of
Meeting. If, however, other matters are properly brought before the meeting, it
is the intention of the persons named in the accompanying form of proxy to vote
the shares represented thereby on such matters in accordance with their best
judgment.

-11-

SHAREHOLDER PROPOSAL

Under the rules of the Securities and Exchange Commission, shareholders
who wish to submit proposals for inclusion in the Proxy Statement for the Annual
Meeting of Shareholders to be held in 2004 must submit such proposals so as to
be received by the Company at 84 West Santa Clara Street, Suite 720, San Jose,
California 95113 not later than January 6, 2004.

BY ORDER OF THE BOARD OF DIRECTORS

Julian N. Stern, Secretary

San Jose, California
April 28, 2003

IMPORTANT

You are cordially invited to attend the meeting in person. Whether or
not you plan to attend the meeting, you are earnestly requested to sign and
return the accompanying proxy in the enclosed envelope.

-12-

HUMAN PHEROMONE SCIENCES, INC.

PROXY SOLICITED BY THE BOARD OF DIRECTORS FOR THE
ANNUAL MEETING OF SHAREHOLDERS TO BE HELD JUNE 18, 2003

(Continued and to be signed on the reverse side)

ANNUAL MEETING OF SHAREHOLDERS OF

HUMAN PHEROMONE SCIENCES, INC.

June 18, 2003

Please date, sign and mail
your proxy card in the
envelope provided as soon
as possible.

Please detach and mail in the envelope provided.

- --------------------------------------------------------------------------------
THE BOARD OF DIRECTORS RECOMMENDS A VOTE "FOR" THE ELECTION OF DIRECTORS.
PLEASE SIGN, DATE AND RETURN PROMPTLY IN THE ENCLOSED ENVELOPE.
PLEASE MARK YOUR VOTE IN BLUE OR BLACK INK AS SOWN HERE [X]
- --------------------------------------------------------------------------------

1. To elect five Directors to hold office until the next Annual Meeting;

NOMINEES

[ ] FOR ALL NOMINEES ( ) William P. Horgan
( ) Bernard I. Grosser, M.D.
[ ] WITHHOLD AUTHORITY ( ) Michael D. Kaufman
FOR ALL NOMINEES ( ) Helen C. Leong
( ) Robert Marx
[ ] FOR ALL EXCEPT
(See instructions below)

INSTRUCTION: To withhold authority to vote for any individual nominee(s), mark
"FOR ALL EXCEPT" and fill in the circle next to each nominee you
wish to withhold, as shown here: (X)
- --------------------------------------------------------------------------------

2. To act upon such other business as may properly come before the meeting.

These items of business are more fully described in the Proxy Statement
accompanying this notice.

Only shareholders of record at the close of business on April 21, 2003, are
entitled to notice of, and to vote at the Annual Meeting and any adjournments or
postponements thereof.

All shareholders are cordially invited to attend the meeting in person. However,
to assure your representation at the meeting, please mark, sign, date and return
the enclosed proxy card as soon as possible in the postage-prepaid envelope
enclosed for that purpose. Any shareholder attending the meeting may vote in
person even if the shareholder has returned a proxy.

WHETHER OR NOT YOU EXPECT TO ATTEND THE ANNUAL MEETING IN PERSON, PLEASE SIGN
AND RETURN THE ENCLOSED PROXY AS SOON AS POSSIBLE IN THE ENCLOSED POSTPAID
ENVELOPE. THANK YOU FOR ACTING PROMPTLY.
- --------------------------------------------------------------------------------

To change the address on your account, please check in the box at
right and indicate your new address in the address space above. Please [ ]
note that changes to the registered name(s) on the account may not be
submitted via this method.
- --------------------------------------------------------------------------------

Signature of Shareholder _______________________________________Date:___________

Note: This proxy must be signed exactly as the name appears hereon. When
shares are held jointly, each holder should sign. When signing as
executor, administrator, attorney, trustee or guardian, please give
full title as such. If the signer is a corporation, please sign full
corporate name by duly authorized officer, giving full title as such.
If signer is a partnership, please sign in partnership name by
authorized person.